TRIMETHOBENZAMIDE HYDROCHLORIDE

Post-LOE

trimethobenzamide hydrochloride

Pfizer

ANDAORALCAPSULE

Approved

Aug 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TRIMETHOBENZAMIDE HYDROCHLORIDE (trimethobenzamide hydrochloride) by Pfizer is obscure, but may involve the chemoreceptor trigger zone (ctz), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. Approved for vomiting, for nausea associated with gastroenteritis. First approved in 2003.

Drug data last refreshed 20h ago

Mechanism of Action

obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic…

Indications (2)

vomiting for nausea associated with gastroenteritis

Worked on TRIMETHOBENZAMIDE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TRIMETHOBENZAMIDE HYDROCHLORIDE

Mechanism of Action

Indications (2)

Clinical Trials (1)